ResMed (RMD) 주식 개요
는 미국 및 전 세계에서 호흡기 질환을 진단, 치료 및 관리하기 위한 의료 기기 및 클라우드 기반 소프트웨어 애플리케이션을 개발, 제조, 유통 및 판매하는 회사입니다. 자세히 보기
강점
위험 분석
우리의 위험 점검에서 RMD에 대한 위험이 감지되지 않았습니다.
RMD Community Fair Values
Create NarrativeSee what 126 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ResMed Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$200.29 |
| 52주 최고가 | US$293.81 |
| 52주 최저가 | US$180.27 |
| 베타 | 0.78 |
| 1개월 변동 | -2.82% |
| 3개월 변동 | -9.15% |
| 1년 변동 | -21.50% |
| 3년 변동 | -8.33% |
| 5년 변동 | -20.05% |
| IPO 이후 변동 | 29,710.60% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jun 26
RMD: Sleep Health Demand And GLP 1 Therapies Will Support Future Upside
Analysts have trimmed their fair value estimate for ResMed by $10 to $260.60. This reflects lower price targets driven by expectations of moderating revenue growth and profit margins, despite ongoing interest in sleep apnea demand trends.분석 기사 • Jun 19
ResMed (RMD) Stock Could Be 30.3% Undervalued After Morgan Stanley Downgrade
Morgan Stanley’s downgrade of ResMed (RMD), citing limited near term profit margin growth and rising competitive risks from Philips and GLP-1 weight-loss drugs, has put fresh attention on how the stock’s story is changing. See our latest analysis for ResMed. At a share price of US$188.63, ResMed has seen its 30 day share price return fall 9.22% and its year to date share price return fall 22.95%, while the 1 year total shareholder return is down 24.08%. This suggests recent downside pressure...Seeking Alpha • Jun 11
ResMed: GLP-1 Threats Are Overstated
Summary My contrarian take on ResMed is that GLP-1 concerns are overstated, and even though a portion of market share will be lost, the remaining portion will be more beneficial to profitability. Other business threats come from PHG's reentrance and Apnimed's drug commercialization. While not to be overlooked, I still see RMD retaining its market dominance. The stock currently trades as if revenues are already declining and margins are contracting. But the opposite is true. Margins far exceed peers, and the top line grows at double digits. I'm upgrading the stock to a strong buy, as I find the current valuation unjust. Read the full article on Seeking AlphaRecent updates
내러티브 업데이트 • Jun 26
RMD: Sleep Health Demand And GLP 1 Therapies Will Support Future Upside
Analysts have trimmed their fair value estimate for ResMed by $10 to $260.60. This reflects lower price targets driven by expectations of moderating revenue growth and profit margins, despite ongoing interest in sleep apnea demand trends.분석 기사 • Jun 19
ResMed (RMD) Stock Could Be 30.3% Undervalued After Morgan Stanley Downgrade
Morgan Stanley’s downgrade of ResMed (RMD), citing limited near term profit margin growth and rising competitive risks from Philips and GLP-1 weight-loss drugs, has put fresh attention on how the stock’s story is changing. See our latest analysis for ResMed. At a share price of US$188.63, ResMed has seen its 30 day share price return fall 9.22% and its year to date share price return fall 22.95%, while the 1 year total shareholder return is down 24.08%. This suggests recent downside pressure...Seeking Alpha • Jun 11
ResMed: GLP-1 Threats Are Overstated
Summary My contrarian take on ResMed is that GLP-1 concerns are overstated, and even though a portion of market share will be lost, the remaining portion will be more beneficial to profitability. Other business threats come from PHG's reentrance and Apnimed's drug commercialization. While not to be overlooked, I still see RMD retaining its market dominance. The stock currently trades as if revenues are already declining and margins are contracting. But the opposite is true. Margins far exceed peers, and the top line grows at double digits. I'm upgrading the stock to a strong buy, as I find the current valuation unjust. Read the full article on Seeking Alpha내러티브 업데이트 • Jun 05
RMD: Sleep Health Partnerships And Acquisitions Will Support Long Term Upside
ResMed's updated analyst price target has shifted lower to $270.60 from $288.21, as analysts factor in revised fair value assumptions and a more conservative future P/E outlook, while maintaining steady expectations for revenue growth and profit margins. Analyst Commentary Recent Street research around ResMed has mixed implications for valuation and execution, with several firms trimming price targets while one major bank has started coverage with a positive stance.
새로운 내러티브 • May 18
GLP 1 Therapies And Sleep Apnea Links Will Drive Powerful Long Term Tailwinds
Catalysts About ResMed ResMed develops and sells sleep and respiratory care devices, masks and cloud-connected software that support treatment and monitoring in the home. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • May 01
GLP 1 Therapies And Margin Pressures Will Challenge Long Term Earnings Sustainability
Catalysts About ResMed ResMed develops and sells sleep and respiratory care devices, masks and cloud-connected software that support treatment in the home. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • May 01
RMD: Distribution Expansion And Execution Discipline Will Drive Future Upside
ResMed's updated analyst price target has slipped by about $8 to reflect slightly more cautious assumptions on revenue growth, profit margins, discount rate and future P/E, with several firms trimming targets even as others maintain a constructive view. Analyst Commentary Recent Street research on ResMed has tilted more cautious on valuation, even as one major firm has initiated with a bullish stance.내러티브 업데이트 • Apr 12
RMD: Distribution Expansion And Margin Strength Will Support Future Upside
ResMed's analyst price target has been nudged lower by about $0.33 as analysts balance a slightly higher discount rate with firmer revenue growth, profit margin assumptions, and modest target increases from several firms alongside a more recent $5 trim from Citi. Analyst Commentary Recent Street research around ResMed reflects a mix of optimism on the company’s execution and growth profile, alongside a more cautious stance on valuation and near term expectations.내러티브 업데이트 • Mar 29
RMD: Higher Earnings Visibility And Margins Will Support Future Upside
Analysts have lifted the consolidated ResMed price target by $15, reflecting updated views on its long term growth, margin profile and P/E assumptions in light of recent research from Citi, RBC Capital, Stifel, KeyBanc and Baird. Analyst Commentary Recent Street research points to a cluster of higher price targets for ResMed, with different teams revisiting their assumptions around growth durability, margin structure and the P/E multiple they are willing to apply.내러티브 업데이트 • Mar 14
RMD: AI Sleep Personalization And New Distribution Hub Will Support Upside
ResMed's analyst price target has edged lower by about $1 to $296.87, as analysts fine tune their models around slightly different fair value, discount rate, revenue growth, profit margin, and future P/E assumptions, while keeping an overall constructive stance. This stance is reflected in a series of recent target increases across the Street.내러티브 업데이트 • Feb 28
RMD: AI Sleep Therapy Personalization Will Support Long Term Upside
ResMed's analyst price target has moved higher by several dollars to reflect a modest adjustment to discount rate assumptions, while multiple firms have raised their targets by $3 to $15. Analysts point to supportive fundamentals for the updated view.내러티브 업데이트 • Feb 14
RMD: AI Sleep Therapy Personalization And Buyback Will Support Long Term Upside
Our updated ResMed narrative reflects a modest lift in the implied analyst price target to about $297.47, with analysts pointing to slightly higher assumed revenue growth, a small improvement in profit margins, and a marginally lower future P/E multiple as key drivers of the change. Analyst Commentary Recent Street research shows a cluster of upward price target revisions for ResMed, with several firms lifting their targets by between $3 and $15.내러티브 업데이트 • Jan 31
RMD: AI Therapy Personalization Will Support Sustained Long Term Upside Potential
Narrative Update on ResMed Analysts have lifted their price targets on ResMed, supporting a modest fair value adjustment to about $296.40 as they factor in updated expectations for growth, profitability, and a slightly lower future P/E assumption. Analyst Commentary Recent Street research on ResMed points to a cluster of price target increases, with several bullish analysts nudging their targets higher by incremental amounts.내러티브 업데이트 • Oct 21
Analyst Commentary Highlights Margin Optimism as ResMed Faces Market Headwinds and Patent Challenge
Analysts have raised their price target for ResMed to $295 from $292, citing improved profit margin expectations and better anticipated gross margin expansion. This comes despite concerns over slower market growth dynamics.분석 기사 • Sep 06
We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Jul 29
Calculating The Intrinsic Value Of ResMed Inc. (NYSE:RMD)
Key Insights ResMed's estimated fair value is US$302 based on 2 Stage Free Cash Flow to Equity Current share price of...Seeking Alpha • Apr 24
ResMed: Cornering The Market In Sleep Solutions
Summary ResMed is a dominant player in healthcare devices with strong margins, recurring revenues, and a near-monopoly, offering a compelling mix of value and growth. The company continually invests in R&D, enhancing its product portfolio, customer experience, and expanding into new markets, justifying its premium share price. Concerns about GLP-1 drugs reducing ResMed's market are countered by data suggesting increased overall health engagement, boosting interest in sleep health solutions. ResMed's consistent innovation and market leadership make it a highly attractive investment, despite its shares already trading at a substantial premium. Read the full article on Seeking AlphaSeeking Alpha • Feb 10
Revisiting ResMed In 2025: Strong Q2 Financial Results And The Growing Demand For Sleep Apnea Solutions
Summary ResMed reported $1.28 billion in revenue and $2.43 EPS, driven by strong demand for AirSense 11 and effective cost management. Rising awareness of sleep apnea, aided by wearable devices like Apple Watch, underscores a significant growth opportunity, with millions still undiagnosed and untreated globally. Concerns over GLP-1 drugs reducing CPAP demand have diminished. Despite an 8.3% stock dip post-earnings, ResMed remains undervalued, trading below its 5-year average P/E ratio, with strong growth prospects supported by innovation and macro trends. Read the full article on Seeking AlphaSeeking Alpha • Feb 01
ResMed: Snoozers Can Be Winners
Summary I believe ResMed is currently overvalued relative to its intrinsic value, making it a good time for investors to take some profits. RMD’s growth has been driven by COVID-19, Philips' product recall, and acquisitions, with a projected growth rate of 9% per year until FY2030. The company's competitive position is strong, with a high ROIC and increasing operating margins, particularly in the SaaS division. Despite the potential impact of GLP-1 drugs, RMD’s demand remains robust, and the company is well-managed with market-leading products. Read the full article on Seeking AlphaSeeking Alpha • Jan 24
ResMed: Fully Valued With Medium-Term Challenges (Rating Downgrade)
Summary ResMed's share price has outperformed the S&P 500 by ~35% since my October 2023 Buy rating. The stock’s outperformance has been driven by a combination of earnings growth and multiple expansion. Operating conditions for ResMed remain positive, but taking a longer-term perspective, investors should be mindful of downside risks related to GLP-1 drugs and the eventual return of Respironics. ResMed’s valuation now looks slightly stretched, however a supportive near-term outlook is sufficient to justify a Hold rating. Read the full article on Seeking AlphaSeeking Alpha • Nov 25
ResMed: Solid Execution, Pricey Valuation
Summary ResMed Inc., a leader in sleep apnea and respiratory care, posted strong 1Q2025 results late in October. The stock is also up nearly 45% year to date and the analyst community has become quite mixed on the stock's prospects, mainly due to valuation. Is there more upside to this rally in 2024 or is some profit taking overdue? An analysis follows in the paragraphs below. Read the full article on Seeking Alpha주주 수익률
| RMD | US Medical Equipment | US 시장 | |
|---|---|---|---|
| 7D | 6.2% | 3.9% | -2.6% |
| 1Y | -21.5% | -20.0% | 20.0% |
수익률 대 산업: RMD은 지난 1년 동안 -20%의 수익을 기록한 US Medical Equipment 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: RMD은 지난 1년 동안 20%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| RMD volatility | |
|---|---|
| RMD Average Weekly Movement | 4.0% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: RMD는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: RMD의 주간 변동성(4%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1989 | 10,600 | Mick Farrell | www.resmed.com |
는 미국 및 전 세계에서 호흡기 질환을 진단, 치료 및 관리하기 위한 의료 기기 및 클라우드 기반 소프트웨어 애플리케이션을 개발, 제조, 유통 및 판매합니다. 이 회사는 수면 및 호흡 건강 부문과 주거용 케어 소프트웨어 부문으로 나뉘어 운영되고 있습니다. 수면 클리닉, 병원 및 가정에서 수면 무호흡증을 진단하고 적정화하기 위한 수면 기록기를 제공하며, 산소포화도, 호흡 노력, 맥박, 비강 흐름 및 코골이를 측정하는 휴대용 진단 기기인 ApneaLink Air, 말초 동맥 톤, 액티그래피 및 산소 측정을 기반으로 AHI를 측정하는 휴대용 클라우드 연결 일회용 진단 기기인 NightOwl, 수면 실험실 솔루션인 EasyCare Tx 등이 그 예입니다.
ResMed Inc. 기초 지표 요약
| RMD 기초 통계 | |
|---|---|
| 시가총액 | US$28.68b |
| 순이익 (TTM) | US$1.52b |
| 매출 (TTM) | US$5.54b |
19.0x
주가수익비율(P/E)5.2x
주가매출비율(P/S)RMD는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| RMD 손익계산서 (TTM) | |
|---|---|
| 매출 | US$5.54b |
| 매출원가 | US$2.09b |
| 총이익 | US$3.44b |
| 기타 비용 | US$1.92b |
| 순이익 | US$1.52b |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 10.52 |
| 총이익률 | 62.18% |
| 순이익률 | 27.44% |
| 부채/자본 비율 | 10.2% |
RMD의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기배당
1.2%
현재 배당 수익률22%
배당 성향기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/26 21:33 |
| 종가 | 2026/06/26 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/06/30 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
ResMed Inc.는 47명의 분석가가 다루고 있습니다. 이 중 14명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Rescott | Baird |
| Michael Polark | Baird |
| Matthew Taylor | Barclays |